CDX-1140 + pembrolizumab

**CDX-1140 + pembrolizumab** is an investigational combination regimen composed of CDX-1140, a fully human agonistic anti-CD40 monoclonal antibody, and pembrolizumab, an anti–programmed cell death protein 1 (PD-1) monoclonal antibody. **CDX-1140** activates antigen-presenting dendritic cells, B cells, and macrophages through CD40 signaling, enhancing antitumor immunity. **Pembrolizumab** blocks the PD-1 immune checkpoint, reactivating T-cell mediated immune responses against cancer cells. The combination is being studied primarily in advanced biliary tract carcinoma (BTC), particularly in the second-line setting, with the rationale that dual activation of both innate and adaptive immunity may overcome tumor immune resistance. Early clinical studies focus on safety, tolerability, and efficacy, with preliminary data suggesting an acceptable safety profile and potential antitumor activity[1][2][3].

Other names

CDX-1140 + Keytruda